Possible underlying mechanisms responsible for aldosterone and mineralocorticoid receptor-dependent renal injury

Journal of Pharmacological Sciences

Volumn 108, Issue 4, 2008, Pages 399-405

  Kiyomoto, Hideyasu ^a   Rafiq, Kazi ^a   Mostofa, Mahbub ^b   Nishiyama, Akira ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b BANGLADESH AGRICULTURAL UNIVERSITY   (Bangladesh)

Author keywords

Aldosterone; Eplerenone; Extracellular signal regulated kinases (ERK) 1 2; Kidney; Mineralocorticoid receptor; Reactive oxygen species (ROS)

Indexed keywords

ALDOSTERONE; EPLERENONE; MINERALOCORTICOID RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RHO KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; CONTROLLED STUDY; ENZYME ACTIVATION; FIBROBLAST; GLOMERULOSCLEROSIS; KIDNEY INJURY; LUNG FIBROSIS; MESANGIUM CELL; NONHUMAN; PODOCYTE; PROTEIN LOCALIZATION; PROTEINURIA; RAT; RECEPTOR UPREGULATION; REVIEW;

EID: 58149154840     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.08R02CR     Document Type: Review

References (52)

1. Simpson SA, Tait JF, Wettstein A, Neher R, Von Euw J, Reichstein T. Isolation from the adrenals of a new crystalline hormone with especially high effectiveness on mineral metabolism. Experientia. 1953;9:333-335.
2. Williams JS, Williams GH. 50th anniversary of aldosterone. J Clin Endocrinol Metab. 2003;88:2364-2372.
3. Fuller PJ, Young MJ. Mechanisms of mineralocorticoid action. Hypertension. 2005;46:1227-1235.
4. Nishimura M, Uzu T, Fujii T, Kuroda S, Nakamura S, Inenaga T, et al. Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis. 1999;33:261-266.
5. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717.
6. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
7. Pitt B, White H, Nicolau J, Martinez F, Gheorghiade M, Aschermann M, et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol. 2005;46:425-431.
8. Weintraub WS, Zhang Z, Mahoney EM, Kolm P, Spertus JA, Caro J, et al. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation. 2005;111:1106-1113.
9. Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004). Hypertens Res. 2006;29 Suppl:S1-S105.
10. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007;115:114-126.
11. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-1187.
12. Rossi GP, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, et al. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension. 2006;48:232-238.
13. Sechi LA, Novello M, Lapenna R, Baroselli S, Nadalini E, Colussi GL, et al. Long-term renal outcomes in patients with primary aldosteronism. JAMA. 2006;295:2638-2645.
14. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, et al. Relationships of plasma renin levels with renal function in patients with primary aldosteronism. Clin J Am Soc Nephrol. 2007;2:722-731.
15. Schjoedt KJ, Andersen S, Rossing P, Tarnow L, Parving HH. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia. 2004;47:1936-1939.
16. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension. 2003;41:64-68.
17. Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis. 2008;51:199-211.
18. Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol. 2006;1:256-262.
19. Sato A, Hayashi K, Saruta T. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens. 2005;18:44-49.
20. Nagase M, Fujita T. Aldosterone and glomerular podocyte injury. Clin Exp Nephrol. 2008;12:233-242.
21. Nishiyama A, Abe Y. Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effects of aldosterone blockade. J Pharmacol Sci. 2006;100:9-16.
22. Mathew JT, Patni H, Chaudhary AN, Liang W, Gupta A, Chander PN, et al. Aldosterone Induces Mesangial Cell Apoptosis both in vivo and in vitro. Am J Physiol Renal Physiol. 2008;295:F73-F81.
23. Nishiyama A, Yao L, Nagai Y, Miyata K, Yoshizumi M, Kagami S, et al. Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension. 2004;43:841-848.
24. Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension. 2007;49:355-364.
25. Nishiyama A, Yao L, Fan Y, Kyaw M, Kataoka N, Hashimoto K, et al. Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability. Hypertension. 2005;45:710-716.
26. Nagai Y, Miyata K, Sun GP, Rahman M, Kimura S, Miyatake A, et al. Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1/2 in rat renal fibroblasts. Hypertension. 2005;46:1039-1045.
27. Terada Y, Kobayashi T, Kuwana H, Tanaka H, Inoshita S, Kuwahara M, et al. Aldosterone stimulates proliferation of mesangial cells by activating mitogen-activated protein kinase 1/2, cyclin D1, and cyclin A. J Am Soc Nephrol. 2005;16:2296-2305.
28. Nishikawa T, Suematsu S, Saito J, Soyama A, Ito H, Kino T, et al. Human renal mesangial cells produce aldosterone in response to low-density lipoprotein (LDL). J Steroid Biochem Mol Biol. 2005;96:309-316.
29. Nagase M, Yoshida S, Shibata S, Nagase T, Gotoda T, Ando K, et al. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol. 2006;17:3438-3446.
30. Quinkler M, Zehnder D, Eardley KS, Lepenies J, Howie AJ, Hughes SV, et al. Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria. Circulation. 2005;112:1435-1443.
31. Suh JM, Yu CT, Tang K, Tanaka T, Kodama T, Tsai MJ, et al. The expression profiles of nuclear receptors in the developing and adult kidney. Mol Endocrinol. 2006;20:3412-3420.
32. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 2003;63:1791-1800.
33. Fan YY, Baba R, Nagai Y, Miyatake A, Hosomi N, Kimura S, et al. Augmentation of intrarenal angiotensin II levels in uninephrectomized aldosterone/salt-treated hypertensive rats; renoprotective effects of an ultrahigh dose of olmesartan. Hypertens Res. 2006;29:169-178.
34. Peng H, Carretero OA, Raij L, Yang F, Kapke A, Rhaleb NE. Antifibrotic effects of N-acetyl-seryl-aspartyl-Lysyl-proline on the heart and kidney in aldosterone-salt hypertensive rats. Hypertension. 2001;37:794-800.
35. Sun GP, Kohno M, Guo P, Nagai Y, Miyata K, Fan YY, et al. Involvements of Rho-kinase and TGF-beta pathways in aldosterone-induced renal injury. J Am Soc Nephrol. 2006;17:2193-2201.
36. Chun TY, Chander P, Kim JW, Pratt JH, Stier CT. Aldosterone, but not angiotensin II, increased profibrotic factors in the kidney of adrenalectomized stroke prone spontaneously hypertensive rats. Am J Physiol Endocrinol Metab. 2008;295:E305-E312.
37. Ma J, Weisberg A, Griffin JP, Vaughan DE, Fogo AB, Brown NJ. Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury. Kidney Int. 2006;69:1064-1072.
38. Yuan J, Jia R, Bao Y. Aldosterone up-regulates production of plasminogen activator inhibitor-1 by renal mesangial cells. J Biochem Mol Biol. 2007;40:180-188.
39. Yaoita E, Kawasaki K, Yamamoto T, Kihara I. Variable expression of desmin in rat glomerular epithelial cells. Am J Pathol. 1990;136:899-908.
40. Nagase M, Matsui H, Shibata S, Gotoda T, Fujita T. Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. Hypertension. 2007;50:877-883.
41. Nagase M, Shibata S, Yoshida S, Nagase T, Gotoda T, Fujita T. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension. 2006;47:1084-1093.
42. Nishikimi T, Akimoto K, Wang X, Mori Y, Tadokoro K, Ishikawa Y, et al. Fasudil, a Rho-kinase inhibitor, attenuates glomerulosclerosis in Dahl salt-sensitive rats. J Hypertens. 2004;22:1787-1796.
43. Miyata K, Rahman M, Shokoji T, Nagai Y, Zhang GX, Sun GP, et al. Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. J Am Soc Nephrol. 2005;16:2906-2912.
44. Otani H, Otsuka F, Inagaki K, Takeda M, Miyoshi T, Suzuki J, et al. Antagonistic effects of bone morphogenetic protein-4 and -7 on renal mesangial cell proliferation induced by aldosterone through MAPK activation. Am J Physiol Renal Physiol. 2007;292:F1513-F1525.
45. Huang W, Xu C, Kahng KW, Noble NA, Border WA, Huang Y. Aldosterone and TGF-β1 synergistically increase PAI-1 and decrease matrix degradation in rat renal mesangial and fibroblast cells. Am J Physiol Renal Physiol. 2008;294:F1287-F1295.
46. Irita J, Okura T, Kurata M, Miyoshi K, Fukuoka T, Higaki J. Osteopontin in rat renal fibroblasts: functional properties and transcriptional regulation by aldosterone. Hypertension. 2008;51:507-513.
47. Funder JW. The nongenomic actions of aldosterone. Endocr Rev. 2005;26:313-321.
48. Good DW, George T, Watts BA 3rd. Aldosterone potentiates 1,25-dihydroxyvitamin D3 action in renal thick ascending limb via a nongenomic, ERK-dependent pathway. Am J Physiol Cell Physiol. 2003;285:C1122-C1130.
49. Mazak I, Fiebeler A, Muller DN, Park JK, Shagdarsuren E, Lindschau C, et al. Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation. 2004;109:2792-2800.
50. Rossol-Haseroth K, Zhou Q, Braun S, Boldyreff B, Falkenstein E, Wehling M, et al. Mineralocorticoid receptor antagonists do not block rapid ERK activation by aldosterone. Biochem Biophys Res Commun. 2004;318:281-288.
51. Ishizawa K, Izawa Y, Ito H, Miki C, Miyata K, Fujita Y, et al. Aldosterone stimulates vascular smooth muscle cell proliferation via big mitogen-activated protein kinase 1 activation. Hypertension. 2005;46:1046-1052.
52. Grossmann C, Benesic A, Krug AW, Freudinger R, Mildenberger S, Gassner B, et al. Human mineralocorticoid receptor expression renders cells responsive for nongenotropic aldosterone actions. Mol Endocrinol. 2005;19:1697-1710.